Pancreatic cancer has a high mortality rate and a poor prognosis, and it is urgent to advance research on its related biomarkers. As an expert in the field of biomarkers, Creative BioMart Biomarker has extensive experience in detecting various tumor-related biomarkers and can provide customers with fast and accurate test results. We provide customers with high-quality pancreatic cancer biomarker detection services to meet customer research needs and help customers shorten the research cycle.
Pancreatic cancer is a common malignant tumor of the digestive system, which has the characteristics of early diagnosis difficult and high degree of malignancy. Therefore, pancreatic cancer has a very high mortality rate and has a poor prognosis. Most pancreatic cancer patients cannot achieve early diagnosis because they do not show clinical symptoms and imaging features in the early stage of the disease. Most patients with pancreatic cancer have developed advanced tumors or metastasized tumors when clinical symptoms appear, thus losing the opportunity to receive effective treatment. For pancreatic cancer, early detection and early diagnosis is the key to improve the cure rate and prognosis. Current diagnostic techniques for pancreatic cancer are mainly invasive endoscopy and imaging techniques, such as computed tomography, magnetic resonance imaging, endoscopic retrograde cholangiopancreatography, and ultrasound endoscopyfine needle aspiration. However, the current diagnostic methods still cannot meet the needs of early diagnosis, and effective biomarkers are specific and sensitive, can significantly promote the early diagnosis of tumors and can be used to distinguish pancreatic cancer from other benign pancreatic diseases. Therefore, it is necessary to conduct research on biomarkers related to pancreatic cancer. For example, CA19-9 is currently approved as a biomarker for pancreatic cancer diagnosis, disease monitoring, and treatment response evaluation. Although biomarkers for the diagnosis of pancreatic cancer have been developed, they are not sufficient to fully realize the early diagnosis of pancreatic cancer. More effective biomarkers need to be introduced to be utilized in combination with CA19-9 to further promote the early diagnosis and disease progress monitoring of pancreatic cancer.
Figure 1. The “future” of pancreatic ductal adenocarcinoma early detection. (Singhi, et al. 2019)
Creative BioMart Biomarker provides high-quality detection services for pancreatic cancer biomarkers that are applicable to a variety of biomarkers. If you do not find detection services for your research object on this webpage, you can find more biomarkers in biomarker menu or contact us to get more help. We have a technical team with rich experience in tumor biomarker detection, as well as multiple technical platforms suitable for biomarker detection, capable of accurate, specific and sensitive detection for various types of samples. If you are seeking pancreatic cancer biomarker detection services, please feel free to contact us, we look forward to being your trusted partner.